Weight management in overweight or obesity: Implications for cancer pathogenesis and prognosis.
作者信息
Wang Yue, Niu Haitao, Lyu Peng, Liu Bing, Wei Junmin
机构信息
National Institutes for Food and Drug Control, Beijing 102629, China.
National Health Commission of the People's Republic of China, Beijing 100044, China.
出版信息
Cancer Pathog Ther. 2025 May 9;3(4):273-275. doi: 10.1016/j.cpt.2025.05.001. eCollection 2025 Jul.
Abstract
摘要
相似文献
1
Weight management in overweight or obesity: Implications for cancer pathogenesis and prognosis.超重或肥胖中的体重管理：对癌症发病机制和预后的影响。
Cancer Pathog Ther. 2025 May 9;3(4):273-275. doi: 10.1016/j.cpt.2025.05.001. eCollection 2025 Jul.
2
Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes.替尔泊肽10毫克和15毫克与司美格鲁肽2.4毫克治疗2型糖尿病患者肥胖和超重的间接比较疗效与安全性
Diabetes Obes Metab. 2025 Jun 19. doi: 10.1111/dom.16508.
3
Interventions to change the behaviour of health professionals and the organisation of care to promote weight reduction in children and adults with overweight or obesity.改变卫生专业人员行为及护理组织方式的干预措施，以促进超重或肥胖儿童及成人减轻体重。
Cochrane Database Syst Rev. 2017 Nov 30;11(11):CD000984. doi: 10.1002/14651858.CD000984.pub3.
4
Gut microbiome-based interventions for the management of obesity in children and adolescents aged up to 19 years.基于肠道微生物群的干预措施用于管理19岁及以下儿童和青少年的肥胖问题。
Cochrane Database Syst Rev. 2025 Jul 10;7(7):CD015875. doi: 10.1002/14651858.CD015875.
5
Mobile health (m-health) smartphone interventions for adolescents and adults with overweight or obesity.移动健康（m-health）智能手机干预措施用于超重或肥胖的青少年和成年人。
Cochrane Database Syst Rev. 2024 Feb 20;2(2):CD013591. doi: 10.1002/14651858.CD013591.pub2.
6
Hormonal contraceptives for contraception in overweight or obese women.超重或肥胖女性避孕用激素避孕药
Cochrane Database Syst Rev. 2016 Aug 18;2016(8):CD008452. doi: 10.1002/14651858.CD008452.pub4.
7
Effect of Intake on Body Weight and Body Fat in Overweight and Obese Adult Subjects: A Systematic Review and Meta-Analysis.超重和肥胖成年受试者摄入对体重和体脂肪的影响：系统评价和荟萃分析。
J Am Nutr Assoc. 2024 Aug;43(6):519-531. doi: 10.1080/27697061.2024.2320192. Epub 2024 Mar 18.
8
Body mass index, weight change, and cancer prognosis: a meta-analysis and systematic review of 73 cohort studies.体重指数、体重变化与癌症预后：73 项队列研究的荟萃分析和系统评价。
ESMO Open. 2024 Mar;9(3):102241. doi: 10.1016/j.esmoop.2024.102241. Epub 2024 Mar 4.
9
Hormonal contraceptives for contraception in overweight or obese women.超重或肥胖女性避孕用激素避孕药。
Cochrane Database Syst Rev. 2013 Apr 30(4):CD008452. doi: 10.1002/14651858.CD008452.pub3.
10
Calcium supplementation for people with overweight or obesity.超重或肥胖人群的钙补充。
Cochrane Database Syst Rev. 2024 May 9;5(5):CD012268. doi: 10.1002/14651858.CD012268.pub2.
引用本文的文献
1
Treatment of NSCLC after chemoimmunotherapy - are we making headway?化疗免疫治疗后非小细胞肺癌的治疗——我们有进展吗？
Nat Rev Clin Oncol. 2025 Aug 14. doi: 10.1038/s41571-025-01061-7.
本文引用的文献
1
Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021.1990年至2021年全球、区域和国家成人超重和肥胖患病率及到2050年的预测：全球疾病负担研究2021的一项预测研究
Lancet. 2025 Mar 8;405(10481):813-838. doi: 10.1016/S0140-6736(25)00355-1. Epub 2025 Mar 3.
2
The GLP-1R agonist semaglutide reshapes pancreatic cancer associated fibroblasts reducing collagen proline hydroxylation and favoring T lymphocyte infiltration.胰高血糖素样肽-1受体激动剂司美格鲁肽重塑胰腺癌相关成纤维细胞，减少胶原蛋白脯氨酸羟化并促进T淋巴细胞浸润。
J Exp Clin Cancer Res. 2025 Jan 20;44(1):18. doi: 10.1186/s13046-024-03263-w.
3
Relationship between visceral obesity and prognosis in patients with stage IVB cervical cancer receiving radiotherapy and chemotherapy.IVB期宫颈癌患者接受放化疗时内脏肥胖与预后的关系
Cancer Pathog Ther. 2023 Sep 20;2(3):180-186. doi: 10.1016/j.cpt.2023.09.002. eCollection 2024 Jul.
4
Burden of disease scenarios for 204 countries and territories, 2022-2050: a forecasting analysis for the Global Burden of Disease Study 2021.204 个国家和地区 2022-2050 年疾病负担情景：2021 年全球疾病负担研究的预测分析。
Lancet. 2024 May 18;403(10440):2204-2256. doi: 10.1016/S0140-6736(24)00685-8.
5
Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.全球疾病负担研究 2021 年在 204 个国家和地区、811 个次国家级地点对 88 种风险因素的全球负担和证据强度：系统分析。
Lancet. 2024 May 18;403(10440):2162-2203. doi: 10.1016/S0140-6736(24)00933-4.
6
Obesity-related T cell dysfunction impairs immunosurveillance and increases cancer risk.肥胖相关的 T 细胞功能障碍会损害免疫监视并增加癌症风险。
Nat Commun. 2024 Apr 2;15(1):2835. doi: 10.1038/s41467-024-47359-5.
7
Association between high body mass index and prognosis of patients with early-stage breast cancer: A systematic review and meta-analysis.高体重指数与早期乳腺癌患者预后的关联：一项系统评价与荟萃分析。
Cancer Pathog Ther. 2023 Apr 5;1(3):205-215. doi: 10.1016/j.cpt.2023.03.002. eCollection 2023 Jul.
8
Impact of body mass index and its change on survival outcomes in patients with early breast cancer: A pooled analysis of individual-level data from BCIRG-001 and BCIRG-005 trials.体重指数及其变化对早期乳腺癌患者生存结局的影响：来自 BCIRG-001 和 BCIRG-005 试验的个体水平数据的汇总分析。
Breast. 2023 Oct;71:1-12. doi: 10.1016/j.breast.2023.07.002. Epub 2023 Jul 5.
9
Body Mass Index and Cancer Risk: An Umbrella Review of Meta-Analyses of Observational Studies.体重指数与癌症风险：观察性研究荟萃分析的伞状综述
Nutr Cancer. 2023;75(4):1051-1064. doi: 10.1080/01635581.2023.2180824. Epub 2023 Feb 21.
10
Understanding the mechanisms underlying obesity in remodeling the breast tumor immune microenvironment: from the perspective of inflammation.从炎症角度理解肥胖重塑乳腺肿瘤免疫微环境的机制
Cancer Biol Med. 2023 Mar 8;20(4):268-86. doi: 10.20892/j.issn.2095-3941.2022.0547.
Zotero 插件